These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32556778)

  • 1. Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session.
    Jia X; Al Rifai M; Liu J; Agarwala A; Gulati M; Virani SS
    Curr Atheroscler Rep; 2020 Jun; 22(8):32. PubMed ID: 32556778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session.
    Al Rifai M; Jia X; Al-Mallah MH; Miedema MD; Martin SS; Virani SS
    Curr Atheroscler Rep; 2019 May; 21(8):31. PubMed ID: 31127398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial.
    Blom DJ; Harada-Shiba M; Rubba P; Gaudet D; Kastelein JJP; Charng MJ; Pordy R; Donahue S; Ali S; Dong Y; Khilla N; Banerjee P; Baccara-Dinet M; Rosenson RS
    J Am Coll Cardiol; 2020 Jul; 76(2):131-142. PubMed ID: 32646561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia.
    Béliard S; Saheb S; Litzler-Renault S; Vimont A; Valero R; Bruckert É; Farnier M; Gallo A
    Arterioscler Thromb Vasc Biol; 2024 Jun; 44(6):1447-1454. PubMed ID: 38695169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
    McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH
    Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia.
    Ginsberg HN; Tuomilehto J; Hovingh GK; Cariou B; Santos RD; Brown AS; Sanganalmath SK; Koren A; Thompson D; Raal FJ
    Cardiovasc Drugs Ther; 2019 Feb; 33(1):69-76. PubMed ID: 30734207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evinacumab for Homozygous Familial Hypercholesterolemia.
    Raal FJ; Rosenson RS; Reeskamp LF; Hovingh GK; Kastelein JJP; Rubba P; Ali S; Banerjee P; Chan KC; Gipe DA; Khilla N; Pordy R; Weinreich DM; Yancopoulos GD; Zhang Y; Gaudet D;
    N Engl J Med; 2020 Aug; 383(8):711-720. PubMed ID: 32813947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
    Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
    Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
    Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
    J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Disease Prevention in Focus: Highlights from the 2019 American Heart Association Scientific Sessions.
    Mehta A; Mahtta D; Gulati M; Sperling LS; Blumenthal RS; Virani SS
    Curr Atheroscler Rep; 2020 Jan; 22(1):3. PubMed ID: 31927694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy.
    Gaudet D; Greber-Platzer S; Reeskamp LF; Iannuzzo G; Rosenson RS; Saheb S; Stefanutti C; Stroes E; Wiegman A; Turner T; Ali S; Banerjee P; Drewery T; McGinniss J; Waldron A; George RT; Zhao XQ; Pordy R; Zhao J; Bruckert E; Raal FJ
    Eur Heart J; 2024 Jul; 45(27):2422-2434. PubMed ID: 38856678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Will evinacumab become the standard treatment for homozygous familial hypercholesterolemia?
    Doggrell SA
    Expert Opin Biol Ther; 2021 Mar; 21(3):299-302. PubMed ID: 33295805
    [No Abstract]   [Full Text] [Related]  

  • 13. Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity.
    Banerjee P; Chan KC; Tarabocchia M; Benito-Vicente A; Alves AC; Uribe KB; Bourbon M; Skiba PJ; Pordy R; Gipe DA; Gaudet D; Martin C
    Arterioscler Thromb Vasc Biol; 2019 Nov; 39(11):2248-2260. PubMed ID: 31578082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lomitapide-a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia.
    Stefanutti C
    Curr Atheroscler Rep; 2020 Jun; 22(8):38. PubMed ID: 32557261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies.
    Raal FJ; Hegele RA; Ruzza A; López JAG; Bhatia AK; Wu J; Wang H; Gaudet D; Wiegman A; Wang J; Santos RD
    Arterioscler Thromb Vasc Biol; 2024 May; 44(5):1156-1164. PubMed ID: 38545781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.
    Ezekowitz JA; O'Connor CM; Troughton RW; Alemayehu WG; Westerhout CM; Voors AA; Butler J; Lam CSP; Ponikowski P; Emdin M; Patel MJ; Pieske B; Roessig L; Hernandez AF; Armstrong PW
    JACC Heart Fail; 2020 Nov; 8(11):931-939. PubMed ID: 33039447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia.
    Gouni-Berthold I; Descamps OS; Fraass U; Hartfield E; Allcott K; Dent R; März W
    Br J Clin Pharmacol; 2016 Dec; 82(6):1412-1443. PubMed ID: 27478094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.
    Gandra SR; Villa G; Fonarow GC; Lothgren M; Lindgren P; Somaratne R; van Hout B
    Clin Cardiol; 2016 Jun; 39(6):313-20. PubMed ID: 27092712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.